Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
head and neck cancer
Pharma
Coherus spurns 'heavily discounted' pricing for new PD-1 med
For the first China-made PD-1 inhibitor to receive FDA approval, Coherus BioSciences “will not engage in heavily discounted pricing,” its CEO said.
Angus Liu
Oct 30, 2023 12:10pm
Vyvanse, Keytruda-Lenvima, Adagene-ADC—Fierce Pharma Asia
Sep 1, 2023 8:50am
Another Keytruda-Lenvima hope shattered at Merck, Eisai
Aug 25, 2023 10:35am
Merck KGaA starts educating HCPs on cancer's wall of resistance
Jun 26, 2023 10:24am
Eisai helps build a head and neck cancer community
Apr 17, 2023 7:30am
ESMO: Keytruda's failed head and neck cancer data show hope
Sep 11, 2022 10:30am